10-K: Odyssey Health Faces Financial Strain, Extends Debt Maturities

Odyssey Health, Inc. has amended its debt agreements with Mast Hill Fund, L.P., extending maturity dates to January 31, 2027, while acknowledging significant going concern risks and a lack of funds to meet obligations.

Summary

• Odyssey Health, Inc. has entered into a Global Amendment with Mast Hill Fund, L.P. to extend the maturity date of its promissory notes to January 31, 2027.
• The company has received one-time waivers for certain events of default related to past non-payment and failure to maintain reserved shares.
• Odyssey Health continues to face substantial doubt about its ability to continue as a going concern, with a significant working capital deficit of $12,129,687 as of July 31, 2026.
• The company has not generated revenue and expects to incur ongoing operating losses.
• There are material weaknesses in internal controls over financial reporting due to insufficient resources and inadequate segregation of duties.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's precarious financial situation, significant going concern warnings, and substantial debt obligations with upcoming maturities.

Positives

• Extension of debt maturity dates to January 31, 2027, provides a temporary reprieve from immediate repayment obligations.
• One-time waivers for specific events of default offer a short-term buffer against acceleration of debt.
• The company has two product candidates, CardioMap and Save-A-Life, in development, though funding constraints have suspended CardioMap's development.
• The company has secured some financing through promissory notes and securities purchase agreements, though insufficient to cover all obligations.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern, as noted by the independent auditor.
• The company has a significant working capital deficit of $12,129,687 as of July 31, 2026.
• Odyssey Health does not currently have sufficient funds to repay its Mast Hill notes at the extended maturity date of January 31, 2027.
• Material weaknesses in internal control over financial reporting have been identified due to insufficient personnel and inadequate segregation of duties.
• The company has accumulated a deficit of $68,475,530 as of July 31, 2026.
• The company's common stock is quoted on the OTCID Basic Market, a lower tier than OTCQB, potentially reducing liquidity and adversely affecting the stock price.

Risks

• Failure to secure additional financing could force the company to curtail, discontinue, or cease operations.
• If noteholders accelerate debt, the company may be forced to seek protection under the U.S. Bankruptcy Code, potentially resulting in a total loss for stockholders.
• The company has insufficient authorized shares to satisfy all potential conversions of its convertible notes, leading to potential liability classification.
• The company's products are in development and require FDA clearance or approval, which has not been obtained, creating uncertainty about commercialization.
• The company's stock is considered a penny stock, subject to additional sales practice requirements for broker-dealers, which may limit trading activity.
• The company's limited operating history and lack of revenue create substantial uncertainty about future results.

Future Outlook

The company's future outlook is highly uncertain, heavily dependent on its ability to secure significant additional financing to meet its obligations and fund its operations. Without additional capital, the company may be forced to scale back or cease operations. The extended debt maturities provide a short-term window to address these critical financing needs.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• Management has evaluated the effectiveness of disclosure controls and procedures and concluded they were not effective due to material weaknesses in internal control over financial reporting.
• Management is committed to improving internal controls by using third-party specialists, increasing independent reconciliations, and potentially appointing additional outside directors.

Industry Context

StockSavvy.ai notes that Odyssey Health operates in the highly competitive and capital-intensive medical device and technology sector. Companies in this space often face significant challenges in product development, regulatory approval, and securing adequate funding, especially in their early stages. The company's focus on novel technologies like CardioMap and Save-A-Life aligns with industry trends towards preventative care and innovative medical solutions, but the current financial distress poses a significant hurdle to realizing this potential.

Comparison to Industry Standards

• Companies in the medical device sector typically require substantial R&D investment and often rely on venture capital or public offerings for funding. Odyssey Health's reliance on debt financing and its inability to secure sufficient capital are significant deviations from typical industry funding models.
• The extended timelines for FDA approval and the high failure rate of product candidates in clinical trials are common industry challenges. Odyssey Health's current development stage and lack of regulatory approvals place it at a disadvantage compared to established players with approved products.
• Many successful medical device companies achieve profitability through licensing agreements or direct sales post-FDA approval. Odyssey Health's current inability to commercialize its products due to funding and regulatory hurdles prevents it from following this path.

Related Party Transactions

• Accounts payable and accrued wages to officers (Joseph M. Redmond and Christine M. Farrell) totaled $1,854,617 as of July 31, 2026.
• Promissory notes payable to officers and directors total $100,000 as of July 31, 2026.

Stakeholder Impact

• Existing stockholders face significant dilution risk from future equity issuances and potential loss of their entire investment if the company fails.
• Creditors, particularly Mast Hill Fund, L.P., face the risk of non-payment at the extended maturity date, potentially leading to accelerated debt and bankruptcy proceedings.
• Employees may face job insecurity due to the company's precarious financial situation and potential cessation of operations.
• Suppliers may face delayed or non-payment of outstanding invoices, as evidenced by the forgiveness of $759,114 in accounts payable by 17 vendors.

Next Steps

• Secure additional financing to meet obligations and fund operations.
• Address material weaknesses in internal controls over financial reporting.
• Continue development of the Save-A-Life device, prioritizing it over CardioMap due to funding constraints.
• Seek FDA clearance or approval for product candidates once funding allows for further development and trials.

Key Dates

Recommendation

The company is in severe financial distress, with a going concern warning from its auditor, substantial debt maturing soon that it cannot repay, and a lack of operating revenue. The extension of debt maturities and waivers provide only temporary relief. Without a significant and immediate capital infusion, the company faces a high probability of bankruptcy, rendering the stock worthless. Investors should sell to avoid further losses.

Keywords

Convertible Notes, Debt Maturity Extension, Going Concern, Financing, Mast Hill Fund, Odyssey Health, Securities Purchase Agreement, Global Amendment